Beta Bionics, Inc.

Beta Bionics, Inc.

NNASDAQ:BBNX
15.21
USD
-1.21
(-7.37%)
-1.85EPS
1.03BMarket Cap
Mar 30Next Earn

Total Valuation

USD

As of September 30, 2026, Beta Bionics, Inc. carries a market capitalization of 1.03B, placing it among publicly traded companies globally. Its enterprise value stands at 797.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.03B
Enterprise Value797.71M

Important Dates

Beta Bionics, Inc.'s next confirmed earnings release is scheduled for March 30, 2027.

Earnings Date3/30/2027

Share Statistics

As of September 30, 2026, Beta Bionics, Inc. has 54.36M shares outstanding.

Shares Outstanding54.36M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 6.70, and the price-to-book ratio stands at 2.57.

PS Ratio6.70
PB Ratio2.57
P/TBV Ratio2.57
P/FCF Ratio-12.93
P/OCF Ratio-14.36

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 6.27 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 797.71M versus a market cap of 1.03B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales6.27

Financial Position

As of September 30, 2026, Beta Bionics, Inc. maintains a current ratio of 8.92, meaning it holds 8.9x the short-term assets needed to cover near-term liabilities.

Current Ratio8.92
Quick Ratio8.04
Debt / Equity1.52
Debt / EBITDA-0.07

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, Beta Bionics, Inc. posted a negative return on equity (ROE) of -23.88, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -21.48, reflecting losses generated across the asset base. The company generates approximately 300,862.88 in revenue per employee across its workforce of 423.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.43 indicates how many times Beta Bionics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-23.88
Return on Assets (ROA)-21.48
Revenue Per Employee300,862.88
Employee Count423.00
Inventory Turnover2.43

Stock Price Statistics

USD

As of the close on November 16, 2026, Beta Bionics, Inc.'s stock has declined approximately 44.04% over the past 52 weeks. The 50-day moving average sits at 18.39, while the 200-day moving average is 14.82.

52-Week Price Change-44.04%
50-Day Moving Average18.39
200-Day Moving Average14.82

Income Statement

USD

Over the twelve months ended September 30, 2026, Beta Bionics, Inc. generated 127.27M in revenue and converted that into -83.12M in net income, yielding earnings per share of -1.85. EBITDA reached -88.23M, while operating income came in at -92.58M.

Revenue127.27M
Gross Profit74.61M
Operating Income-92.58M
Pretax Income-83.12M
Net Income-83.12M
EBITDA-88.23M
EBIT-92.58M
Earnings Per Share (EPS)-1.85

Balance Sheet

USD

As of September 30, 2026, Beta Bionics, Inc. holds 240.20M in cash and equivalents against 6.10M in total debt, resulting in a net debt position of -81.55M. Total book value stands at 401.38M, with working capital of 260.11M providing operational flexibility.

Cash & Cash Equivalents240.20M
Total Debt6.10M
Net Debt-81.55M
Equity (Book Value)401.38M
Book Value Per Share7.38
Working Capital260.11M

Cash Flow

USD

Beta Bionics, Inc. produced -59.37M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -6.59M in capital expenditures, free cash flow totaled -65.96M - equivalent to -1.47 per share.

Operating Cash Flow-59.37M
Capital Expenditures-6.59M
Free Cash Flow-65.96M
FCF Per Share-1.47

Margins

Over the twelve months ended September 30, 2026, Beta Bionics, Inc. posted a gross margin of 58.63, reflecting its pricing power and cost economics. The operating margin of -72.75 and net profit margin of -65.31 provide insight into operational efficiency.

Gross Margin58.63
Operating Margin-72.75
Pretax Margin-65.31
Profit Margin-65.31
EBITDA Margin-69.33

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -7.74: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -16.19, meaning Beta Bionics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-16.19
FCF Yield-7.74

Scores

As of September 30, 2026, Beta Bionics, Inc. has an Altman Z-Score of 13.52, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score13.52